Palatin Technologies, Inc. (NYSEAMERICAN:PTN) was the target of a significant drop in short interest during the month of March. As of March 29th, there was short interest totalling 15,482,227 shares, a drop of 1.7% from the March 15th total of 15,754,581 shares. Approximately 8.1% of the company’s shares are short sold. Based on an average daily volume of 583,546 shares, the days-to-cover ratio is presently 26.5 days.
Shares of Palatin Technologies stock traded up $0.03 on Friday, reaching $1.24. The company’s stock had a trading volume of 594,920 shares, compared to its average volume of 874,978. Palatin Technologies has a 52-week low of $0.59 and a 52-week high of $1.36.
Palatin Technologies (NYSEAMERICAN:PTN) last posted its quarterly earnings data on Tuesday, February 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.02). During the same period in the previous year, the firm earned $0.01 earnings per share.
A number of brokerages have recently weighed in on PTN. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Palatin Technologies in a research note on Friday, January 11th. TheStreet lowered Palatin Technologies from a “c-” rating to a “d” rating in a research note on Tuesday, February 19th. Finally, Zacks Investment Research upgraded Palatin Technologies from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Wednesday, April 17th.
TRADEMARK VIOLATION NOTICE: This story was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/palatin-technologies-inc-ptn-sees-large-decline-in-short-interest.html.
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Read More: Understanding Stock Ratings
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.